Regeneron Pharmaceuticals (REGN) Other Non-Current Liabilities (2009 - 2026)

Regeneron Pharmaceuticals has reported Other Non-Current Liabilities for 18 years, with the latest figure at $2.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 26.98% year-over-year to $2.1 billion; the trailing twelve-month figure through Mar 2026 stood at $2.1 billion (up 26.98% YoY), and the FY2025 full-year result was $2.0 billion, up 28.47% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $2.1 billion, up from $2.0 billion in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $2.1 billion in Q1 2026, with the low at $43.7 million in Q3 2023.
• Average Other Non-Current Liabilities over 5 years is $1.2 billion, with a median of $908.5 million recorded in 2024.
• Year-over-year, Other Non-Current Liabilities slumped 92.7% in 2023 and soared 3432.27% in 2024.
• Tracing REGN's Other Non-Current Liabilities over 5 years: stood at $638.0 million in 2022, then surged by 33.87% to $854.1 million in 2023, then surged by 83.98% to $1.6 billion in 2024, then advanced by 28.47% to $2.0 billion in 2025, then advanced by 5.32% to $2.1 billion in 2026.
• The last three Other Non-Current Liabilities figures came in at $2.1 billion (Q1 2026), $2.0 billion (Q4 2025), and $1.9 billion (Q3 2025), per Business Quant data.

Peer Comparison